Table 2.
Event rates per 100 patient‐years, annualized absolute risk reduction, and elevation for 1 year of treatment with vericiguat are shown for the primary composite endpoint, total HF hospitalizations (first and recurrent), CV hospitalization, and all‐cause death
| N (%) | Per 100 patient‐years | N (%) | Per 100 patient‐years | Per 100 patient‐years | ||
|---|---|---|---|---|---|---|
| Vericiguat (n = 1798) | Placebo (n = 1806) | Annualized ARR (%) | ||||
| Patients with baseline NT‐proBNP in Q1–Q3 | Primary composite | 506 (28.1) | 24.5 | 619 (34.3) | 31.7 | 7.2 |
| CV death | 190 (10.6) | 7.9 | 240 (13.3) | 10.1 | 2.2 | |
| HF hospitalization (first) | 406 (22.6) | 19.6 | 504 (27.9) | 25.8 | 6.2 | |
| Total HF hospitalizations (first and recurrent) | 725 (40.3) | 30.2 | 891 (49.3) | 37.7 | 7.5 | |
| CV hospitalization | 594 (33.0) | 31.4 | 698 (38.6) | 39.7 | 8.3 | |
| All‐cause death | 237 (13.2) | 9.8 | 286 (15.8) | 12.1 | 2.3 | |
| Vericiguat (n = 616) | Placebo (n = 585) | Annualized ARR (%) | ||||
| Patients with baseline NT‐proBNP in Q4 | Primary composite | 355 (57.6) | 73.6 | 302 (51.6) | 63.6 | −10.0 |
| CV death | 208 (33.8) | 32.0 | 169 (28.9) | 27.1 | −4.9 | |
| HF hospitalization (first) | 251 (40.7) | 52.0 | 209 (35.7) | 44.0 | −8.0 | |
| Total HF hospitalization (first and recurrent) | 432 (70.1) | 66.8 | 392 (67.0) | 63.1 | −3.7 | |
| CV hospitalization | 304 (49.4) | 68.0 | 271 (46.3) | 63.0 | −5.0 | |
| All‐cause death | 256 (41.6) | 39.4 | 211 (36.1) | 33.8 | −5.6 | |
ARR, annualized absolute risk reduction; CV, cardiovascular; HF, heart failure; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.